DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $28,712,000 | +1.0% | 111,160 | -0.9% | 2.41% | +9.1% |
Q2 2022 | $28,426,000 | -14.2% | 112,124 | -0.7% | 2.21% | +3.2% |
Q1 2022 | $33,122,000 | +13.0% | 112,917 | +26.7% | 2.14% | +13.8% |
Q4 2021 | $29,322,000 | +8.0% | 89,122 | -0.1% | 1.88% | -2.6% |
Q3 2021 | $27,159,000 | +13.0% | 89,210 | -0.4% | 1.93% | +12.8% |
Q2 2021 | $24,036,000 | +18.8% | 89,565 | -0.4% | 1.71% | +6.7% |
Q1 2021 | $20,239,000 | -4.5% | 89,918 | -5.8% | 1.61% | -6.6% |
Q4 2020 | $21,197,000 | +3.7% | 95,424 | +0.5% | 1.72% | -7.3% |
Q3 2020 | $20,446,000 | +19.6% | 94,952 | -1.8% | 1.86% | +9.8% |
Q2 2020 | $17,092,000 | +28.5% | 96,656 | +0.6% | 1.69% | +4.5% |
Q1 2020 | $13,298,000 | -10.4% | 96,080 | -0.6% | 1.62% | +9.5% |
Q4 2019 | $14,840,000 | +2.5% | 96,689 | -3.5% | 1.48% | -5.8% |
Q3 2019 | $14,476,000 | -1.1% | 100,227 | -2.1% | 1.57% | +0.4% |
Q2 2019 | $14,634,000 | +7.0% | 102,396 | -1.1% | 1.56% | +4.1% |
Q1 2019 | $13,672,000 | +32.0% | 103,562 | +3.1% | 1.50% | +11.1% |
Q4 2018 | $10,361,000 | +0.9% | 100,480 | +6.3% | 1.35% | +17.3% |
Q3 2018 | $10,272,000 | +8.1% | 94,536 | -1.8% | 1.15% | -3.0% |
Q2 2018 | $9,498,000 | +2.4% | 96,249 | +1.6% | 1.19% | -1.7% |
Q1 2018 | $9,276,000 | +4.6% | 94,741 | -0.8% | 1.21% | +5.8% |
Q4 2017 | $8,867,000 | +2.7% | 95,533 | -5.1% | 1.14% | -1.3% |
Q3 2017 | $8,633,000 | -4.1% | 100,640 | -5.7% | 1.16% | -6.2% |
Q2 2017 | $9,006,000 | -6.8% | 106,722 | -5.5% | 1.23% | -8.0% |
Q1 2017 | $9,664,000 | -43.1% | 112,986 | -48.2% | 1.34% | -19.4% |
Q4 2016 | $16,986,000 | +8.0% | 218,223 | +8.8% | 1.66% | +28.3% |
Q3 2016 | $15,724,000 | -30.5% | 200,592 | -10.5% | 1.30% | -28.8% |
Q2 2016 | $22,631,000 | -7.5% | 224,073 | -13.2% | 1.82% | +2.7% |
Q1 2016 | $24,478,000 | -4.5% | 258,047 | -6.5% | 1.77% | +1.0% |
Q4 2015 | $25,643,000 | -2.0% | 276,084 | -10.1% | 1.75% | +4.3% |
Q3 2015 | $26,167,000 | -7.2% | 307,089 | -6.7% | 1.68% | +8.7% |
Q2 2015 | $28,185,000 | -1.8% | 329,300 | -2.6% | 1.55% | +1.1% |
Q1 2015 | $28,713,000 | -14.5% | 338,196 | -13.7% | 1.53% | -5.8% |
Q4 2014 | $33,602,000 | +10.1% | 392,042 | -2.4% | 1.62% | +9.4% |
Q3 2014 | $30,512,000 | -6.0% | 401,577 | -2.6% | 1.48% | -2.8% |
Q2 2014 | $32,461,000 | +3.1% | 412,313 | -1.8% | 1.53% | +0.5% |
Q1 2014 | $31,485,000 | -5.4% | 419,804 | -2.6% | 1.52% | -4.5% |
Q4 2013 | $33,272,000 | +9.6% | 430,981 | -1.6% | 1.59% | +1.1% |
Q3 2013 | $30,365,000 | +4.2% | 438,044 | -4.9% | 1.57% | +0.1% |
Q2 2013 | $29,144,000 | – | 460,411 | – | 1.57% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |